Association of neutrophil-to-lymphocyte ratio with severe radiation-induced mucositis in pharyngeal or laryngeal cancer patients: a retrospective study

Table 2 Univariate analysis for grade 3 mucositis in patients receiving radiotherapy for pharyngeal or laryngeal cancer

Variable	Category (Reference)	OR	95% CI	p-value
Sex	Male (Female)	0.86	0.18 – 4.06	0.846
Age		1.00	0.96 – 1.05	0.894
BMI (kg/m²)		1.04	0.93 – 1.16	0.521
Smoking (pack-years)		1.02	1.00 – 1.03	0.048
EOCG PS	> 2 (0 or 1)	0.17	0.02 – 1.43	0.103
Diabetes mellitus	With (Without)	0.79	0.28 – 2.20	0.653
Primary tumor location	Hypopharynx (Larynx)	1.18	0.38 – 3.71	0.775
Stage	III, IV (I, II)	1.10	0.37 – 3.32	0.866
Therapy	BRT or CRT (Radiotherapy alone)	3.27	0.67 – 16.00	0.145
Radiotherapy method	IMRT (3D-CRT)	1.43	0.63 – 3.21	0.393
NLR		1.09	1.02 – 1.16	0.016
Concentration of albumin		1.42	0.62 – 3.24	0.404
Concentration of hemoglobin		1.07	0.84 – 1.35	0.593
Concentration of urea nitrogen		1.03	0.97 – 1.09	0.390
Concentration of creatinine		0.97	0.26 – 3.56	0.959

Abbreviations: BMI Body mass index, EOCG PS Eastern Cooperative Oncology Group performance status, NLR Neutrophil-to-lymphocyte ratio, BRT Bioradiotherapy (cetuximab with radiotherapy), CRT Chemotherapy (cisplatin or carboplatin with radiotherapy), IMRT Intensity-modulated radiotherapy, 3D-CRT Three-dimensional conformal radiotherapy, OR Odds ratio, and CI Confidence interval

ISSN: 1471-2407